Hematologic Malignancy
Classic Hodgkin Lymphoma
CI-CAN-00002375CHLExplore in graph →
Hematologic41 active trials3 approved drugs
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00002375CHLExplore in graph →
Clinical trials
114 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (14)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03907488 | Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma | active not recruiting | Phase 3 | 994 | National Cancer Institute (NCI)NIH | 3 | Aug 4, 2026 | clinicaltrials |
| NCT02166463 | Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma | active not recruiting | Phase 3 | 600 | National Cancer Institute (NCI)NIH | 3 |
| Jul 29, 2026 |
| clinicaltrials |
Data updated 22 days agoSource updated Aug 4, 2026source: clinicaltrials